News | November 07, 2025
Philips reiterates FY25 outlook following steady Q3 performance
Adjusted EBITDA increased by 12.3 per cent to $531 million, up from $516 million in the same period last year
Adjusted EBITDA increased by 12.3 per cent to $531 million, up from $516 million in the same period last year
Bayer remains a key partner in Ginkgo Bioworks’ growing agricultural biologicals platform
The study demonstrated strong clinical outcomes, with 94.8 per cent of subjects remaining free from major target limb amputation at one year
The expanded approval allows Kerendia to be prescribed to heart failure patients with a LVEF of 40% or more
Glenmark will begin distribution in November 2025
Kulzer has consolidated the production of its core product, artificial teeth, at its facility in Germany
The company has introduced an innovative Dual Release Proton Pump Inhibitor (PPI) tablet, a next-generation therapy for patients suffering from moderate to severe or treatment resistant gastroesophageal reflux disease
The FDA’s review also revealed delays in Philips’ internal investigations, with 54 inquiries failing to meet targeted completion dates—23 of which were delayed by more than 100 days
The FW500 is designed to meet the evolving needs of mid-sized diagnostic laboratories
Subscribe To Our Newsletter & Stay Updated
